Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prasun Subedi

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Pharmacoeconomics|July 27, 2002
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United StatesCynthia S Palmer, Mark J C Nuijten, Jordana K Schmier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Treatment dynamics of newly marketed drugs and implications for comparative effectiveness researchJoshua J Gagne, Katsiaryna Bykov, Richard J Willke, et al.
Cancer Medicine|December 10, 2015
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasPengxiang Li, Yu-Ning Wong, Katrina Armstrong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
A Review of Empirical Analyses of Disinvestment InitiativesJames D Chambers, Mark N Salem, Brittany N D'Cruz, et al.
Applied Health Economics and Health Policy|November 11, 2016
Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product ApprovalJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United StatesJoshua D Brown, Rich Sheer, Margaret Pasquale, et al.
Journal for Immunotherapy of Cancer|May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatmentHoward L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Pharmacoeconomics|July 27, 2002
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United StatesCynthia S Palmer, Mark J C Nuijten, Jordana K Schmier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Treatment dynamics of newly marketed drugs and implications for comparative effectiveness researchJoshua J Gagne, Katsiaryna Bykov, Richard J Willke, et al.
Cancer Medicine|December 10, 2015
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy erasPengxiang Li, Yu-Ning Wong, Katrina Armstrong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 18, 2017
A Review of Empirical Analyses of Disinvestment InitiativesJames D Chambers, Mark N Salem, Brittany N D'Cruz, et al.
Applied Health Economics and Health Policy|November 11, 2016
Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product ApprovalJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United StatesJoshua D Brown, Rich Sheer, Margaret Pasquale, et al.
Journal for Immunotherapy of Cancer|May 19, 2019
The promise of Immuno-oncology: implications for defining the value of cancer treatmentHoward L Kaufman, Michael B Atkins, Prasun Subedi, et al.
Pageof 2